The 2009 Influenza Pandemic: Promising Lessons For Antiviral Therapy For Future Outbreaks

被引:17
作者
Bavagnoli, L. [1 ]
Maga, G. [1 ]
机构
[1] IGM CNR, Inst Mol Genet, I-27100 Pavia, Italy
关键词
Antigenic shift; Antigenic drift; Antivirals; Host-pathogen relationships; Influenza A virus; Influenza Pandemic; VIRUS NS1 PROTEIN; SIALIDASE FUSION PROTEIN; INHIBITOR-RESISTANT INFLUENZA; CELL SIGNALING PATHWAYS; PRE-MESSENGER-RNAS; NF-KAPPA-B; A-VIRUS; IN-VIVO; NUCLEAR EXPORT; PHOSPHATIDYLINOSITOL-3-KINASE PI3K;
D O I
10.2174/092986711798194397
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The influenza A virus is the main circulating influenza virus in the human population. It can cause disease also in birds and other mammals and is responsible for annual epidemics and occasional pandemics. The most known and deadly pandemic was the "Spanish flu" (influenza type A/H1N1), which struck the human population between 1918 and 1919, with probably the heaviest toll ever recorded in terms of human lives. The most recent flu pandemic, caused in 2009 by the swine-origin reassortant virus (pH1N1), has raised several critical issues in terms of our preparedness in responding fast to new pandemic influenza strains. Probably, the most instructive lesson that has been learned from the 2009 pandemic, was that the speed of manufacturing and distributing an effective vaccine will not be able to keep up with the pace of a rapidly spreading pandemic virus, failing to grant accessibility to the vaccine for a significant percentage of the susceptible population, before the onset of the pandemic peak. Thus, our first and most effective line of defense against a pandemic influenza virus, particularly in the early phases, are the antiviral drugs. Here we analyze our current understanding of the influenza pandemic viruses, in general, and of the pH1N1 in particular, along with the most recent approaches being pursued to design new anti-influenza drugs.
引用
收藏
页码:5466 / 5475
页数:10
相关论文
共 117 条
[1]
Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations [J].
Abed, Y ;
Goyette, N ;
Boivin, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :556-559
[2]
Agency H.P., 2009, EURO SURVEILL, V14
[3]
[Anonymous], PLOS PATHOGENS
[4]
Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses [J].
Basler, Christopher F. ;
Aguilar, Patricia V. .
ANTIVIRAL RESEARCH, 2008, 79 (03) :166-178
[5]
Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an Immunocompromised child [J].
Baz, Mariana ;
Abed, Yacine ;
McDonald, Jane ;
Boivin, Guy .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) :1555-1561
[6]
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection [J].
Belser, Jessica A. ;
Lu, Xiuhua ;
Szretter, Kristy J. ;
Jin, Xiaoping ;
Aschenbrenner, Laura M. ;
Lee, Alice ;
Hawley, Stephen ;
Kim, Do Hyong ;
Malakhov, Michael P. ;
Yu, Mang ;
Fang, Fang ;
Katz, Jacqueline M. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (10) :1493-1499
[7]
The biology of influenza viruses [J].
Bouvier, Nicole M. ;
Palese, Peter .
VACCINE, 2008, 26 :D49-D53
[8]
NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia [J].
Breccia, Massimo ;
Alimena, Giuliana .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (11) :1157-1176
[9]
Genetic divergence of influenza A NS1 gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates from previous seasonal epidemics [J].
Campanini, Giulia ;
Piralla, Antonio ;
Paolucci, Stefania ;
Rovida, Francesca ;
Percivalle, Elena ;
Maga, Giovanni ;
Baldanti, Fausto .
VIROLOGY JOURNAL, 2010, 7
[10]
GENETIC REASSORTMENT BETWEEN AVIAN AND HUMAN INFLUENZA-A VIRUSES IN ITALIAN PIGS [J].
CASTRUCCI, MR ;
DONATELLI, I ;
SIDOLI, L ;
BARIGAZZI, G ;
KAWAOKA, Y ;
WEBSTER, RG .
VIROLOGY, 1993, 193 (01) :503-506